# Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

> **NCT07407920** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 120 (estimated)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Early Stage HER2-Positive Breast Carcinoma
- Early Stage Triple-Negative Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Hormone Therapy
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Pertuzumab
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT07407920
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-09
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07407920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07407920, "Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07407920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*